| Thursday | ||||
Soligenix announced… Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) demonstrating rapid-onset, broad-spectrum, neutralizing antibody and cell-mediated immunity is confirmed using full-length Spike protein antigens. The article titled, "Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice," has been posted as an accelerated preprint on bioRxiv. This work will continue under a $1.5M Small Business Innovation Research grant awarded to Soligenix in December 2020. | ||||
| Over a week ago | ||||
Expects peak annual net… Expects peak annual net sales of SGX301 in the U.S. to exceed $90M, with the total addressable worldwide market estimated at approximately $250M annually. Expects to begin rolling NDA submission for SGX301 in Q2. Expects total U:S. revenues during 10-year forecast period to be above $700M. | ||||
| Over a month ago | ||||
Soligenix announced that… Soligenix announced that the Hong Kong Registrar of Patents has granted a patent for the application titled "Formulations and Methods of Treatment of Skin Conditions", No. 16102842.8, published on January 29 under Publication No. 1214771 B. The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment of cutaneous T-cell lymphoma, or CTCL, similar to those granted in Europe in 2020. Synthetic hypericin is the active pharmaceutical ingredient in SGX301. This new patent is the first granted in Hong Kong and expands on Soligenix's comprehensive patent estate, which includes protection on the composition of the purified synthetic hypericin, methods of synthesis and therapeutic methods of use in both CTCL and psoriasis, and is being pursued worldwide. | ||||
Management discusses the… Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link | ||||
Management discusses U.S.… Management discusses U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link | ||||
Management discusses U.S.… Management discusses U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link | |
Management discusses the… Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link | |
Management discusses the… Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link | |
Soligenix has signed an… Soligenix has signed an exclusive Supply, Distribution and Services Agreement with Daavlin. Securing long-term supply and distribution of a commercially ready light device is an integral component of the regulatory and commercial strategy for SGX301 for the treatment of cutaneous T-cell lymphoma. The company's corporate headquarters and manufacturing plant are located in Bryan, Ohio. Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL. Upon approval of SGX301 by the FDA, Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of the device from Daavlin; and Daavlin will exclusively distribute and sell the SGX301 light device to Soligenix, physicians and patients. |